Overall, PPARα focuses on improving energy metabolism and lipid homeostasis, LXR exhibits metabolic contradictions (improving cholesterol metabolism but potentially worsening fatty liver), and FXR demonstrates greater potential in regulating blood glucose through multi-target synergy and improving metabolic disorders. The gene discussed is NR1H4; the disease is Other metabolic disease.